Peer-influenced content. Sources you trust. No registration required. This is HCN.

NSCLC: FDA Breakthrough Therapy Designation for Targeted EGFR Inhibitor

A “breakthrough therapy” designation has been granted by the FDA to CLN-081 for the treatment of a subset of non-small cell lung cancer. The designation applies to use of the agent by patients with locally advanced or metastatic EGFR-mutated NSCLC who previously received chemotherapy and comes as a phase 1/phase 2a clinical trial is underway.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form